CommercialCoverageMedium impact
Omnitrope - Growth Hormone Coverage Update
Blue Cross Blue Shield of Rhode Island·RI · Endocrinology, Pediatrics·Physician / Facility
Effective date
Dec 1, 2023
We identified it
Jun 19, 2026
Summary
BCBSRI has added Omnitrope as an additional preferred brand growth hormone option for commercial plans effective December 1, 2023. This expansion provides more coverage options during the ongoing growth hormone shortage, while Norditropin and Genotropin remain covered as preferred brands.
Action Required
Immediately: Billing team should update prior authorization systems and coverage verification processes to include Omnitrope as a preferred brand growth hormone option for BCBSRI commercial patients. Update coverage verification scripts to inform patients that Omnitrope is now available as an alternative if other growth hormones are unavailable due to shortages.